Both companies are longtime leaders in the pharmaceutical industry and have been making breakthroughs and delivering ...

Nearly 75% of Americans are classified as overweight or obese. Addressing our nation's health crisis requires much more than ...

Although Novo will still make a mind-blowing amount of money from its existing obesity drugs in the coming years (its ...

Unless the government intervenes to lower the price or forces insurers to cover the drugs, they will remain out of range for ...

When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion in sales in 2023, it shows no ...

Plenty of people want to lose weight in 2025, but here's why many may actually get there thanks to GLP-1 drugs.

No one has ever known so much about healthy eating and been less successful at following her own advice.

Whether this year’s big job commitments sink or swim will be known in time. But for now, let’s explore the dreams.

Whether this year’s big job commitments sink or swim will be known in time. But for now, let’s explore the dreams.

Patients taking a compounded alternative to Eli Lilly's weight loss drug Zepbound will need to transition to the name-brand ...

Mounjaro and Ozempic are both GLP-1 receptors that can be used to help people with diabetes. The treatments are also ...

The growing popularity of GLP-1 receptor agonists—including Ozempic and Wegovy from Novo Nordisk, and Mounjaro and Zepbound ...